ARID1A loss in neuroblastoma promotes the adrenergic-to-mesenchymal transition by regulating enhancer-mediated gene expression
暂无分享,去创建一个
A. Look | T. Tao | B. Abraham | Cigall Kadoch | Adam D. Durbin | M. Zimmerman | Hui Shi | Ting Tao | Mark W. Zimmerman
[1] P. Northcott,et al. Large 1p36 Deletions Affecting Arid1a Locus Facilitate Mycn-Driven Oncogenesis in Neuroblastoma , 2020, Cell reports.
[2] Thomas P. Howard,et al. BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors , 2019, Nature Communications.
[3] C. D. Savci-Heijink,et al. A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma , 2019, Nature Communications.
[4] Cigall Kadoch,et al. Chromatin regulatory mechanisms and therapeutic opportunities in cancer , 2019, Nature Cell Biology.
[5] J. Ranish,et al. Modular Organization and Assembly of SWI/SNF Family Chromatin Remodeling Complexes , 2018, Cell.
[6] C. Lareau,et al. A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation , 2018, Nature Cell Biology.
[7] F. Westermann,et al. TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets , 2018, Nature Communications.
[8] R. Young,et al. Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry , 2018, Nature Genetics.
[9] Devin K Porter,et al. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers , 2017, eLife.
[10] E. Barillot,et al. Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries , 2017, Nature Genetics.
[11] Y. Kaneda,et al. Genetic regulation of the RUNX transcription factor family has antitumor effects , 2017, The Journal of clinical investigation.
[12] Maria C. Lecca,et al. Neuroblastoma is composed of two super-enhancer-associated differentiation states , 2017, Nature Genetics.
[13] P. Park,et al. The SWI/SNF chromatin remodelling complex is required for maintenance of lineage specific enhancers , 2017, Nature Communications.
[14] A. Look,et al. The pre-rRNA processing factor DEF is rate limiting for the pathogenesis of MYCN-driven neuroblastoma , 2017, Oncogene.
[15] Shawn M. Gillespie,et al. SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation , 2016, Nature Genetics.
[16] P. Park,et al. ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice , 2016, Nature Genetics.
[17] Andrew D. Rouillard,et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..
[18] Fidel Ramírez,et al. deepTools2: a next generation web server for deep-sequencing data analysis , 2016, Nucleic Acids Res..
[19] Finbarr O'Sullivan,et al. The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro. , 2015, Cancer letters.
[20] Qing-Yu He,et al. ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization , 2015, Bioinform..
[21] G. Crabtree,et al. Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics , 2015, Science Advances.
[22] Steven L Salzberg,et al. HISAT: a fast spliced aligner with low memory requirements , 2015, Nature Methods.
[23] O. Delattre,et al. Recent insights into the biology of neuroblastoma , 2014, International journal of cancer.
[24] T. Tan,et al. Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients , 2014, EMBO molecular medicine.
[25] Neville E. Sanjana,et al. Improved vectors and genome-wide libraries for CRISPR screening , 2014, Nature Methods.
[26] W. Hahn,et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers , 2014, Nature Medicine.
[27] Ming Yu,et al. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation , 2013, Genes & development.
[28] David A. Scott,et al. Genome engineering using the CRISPR-Cas9 system , 2013, Nature Protocols.
[29] William A Weiss,et al. Neuroblastoma and MYCN. , 2013, Cold Spring Harbor perspectives in medicine.
[30] Eli J. Fine,et al. DNA targeting specificity of RNA-guided Cas9 nucleases , 2013, Nature Biotechnology.
[31] Michael A. Dyer,et al. Neuroblastoma: developmental biology, cancer genomics and immunotherapy , 2013, Nature Reviews Cancer.
[32] G. Crabtree,et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy , 2013, Nature Genetics.
[33] D. Lane,et al. Def defines a conserved nucleolar pathway that leads p53 to proteasome-independent degradation , 2013, Cell Research.
[34] Jeffry D. Sander,et al. Efficient In Vivo Genome Editing Using RNA-Guided Nucleases , 2013, Nature Biotechnology.
[35] F. Westermann,et al. 1p36 tumor suppression--a matter of dosage? , 2012, Cancer research.
[36] Giovanni Parmigiani,et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma , 2012, Nature Genetics.
[37] Qian Wang,et al. GFOLD: a generalized fold change for ranking differentially expressed genes from RNA-seq data , 2012, Bioinform..
[38] D. Neuberg,et al. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. , 2012, Cancer cell.
[39] Steven L Salzberg,et al. Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.
[40] Tian-Li Wang,et al. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. , 2011, Cancer research.
[41] Meng Li,et al. Somatic Mutations in the Chromatin Remodeling Gene ARID1A Occur in Several Tumor Types , 2011, Human mutation.
[42] S. Wiseman,et al. Loss of BAF250a (ARID1A) is frequent in high‐grade endometrial carcinomas , 2011, The Journal of pathology.
[43] I. Shih,et al. Mutation and Loss of Expression of ARID1A in Uterine Low-grade Endometrioid Carcinoma , 2011, The American journal of surgical pathology.
[44] Philip Machanick,et al. MEME-ChIP: motif analysis of large DNA datasets , 2011, Bioinform..
[45] Richard A. Moore,et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.
[46] Tian-Li Wang,et al. Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.
[47] J. Maris. Recent advances in neuroblastoma. , 2010, The New England journal of medicine.
[48] W. Huber,et al. which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .
[49] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[50] Clifford A. Meyer,et al. Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.
[51] P. White,et al. Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas , 2008, Oncogene.
[52] K. Huber. The sympathoadrenal cell lineage: specification, diversification, and new perspectives. , 2006, Developmental biology.
[53] E. Moran,et al. The c-myc gene is a direct target of mammalian SWI/SNF-related complexes during differentiation-associated cell cycle arrest. , 2006, Cancer research.
[54] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[55] S. Gregory,et al. Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma , 2005, Oncogene.
[56] W. Hahn,et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers , 2014, Nature Medicine.
[57] C. Roberts,et al. ARID1A mutations in cancer: another epigenetic tumor suppressor? , 2013, Cancer discovery.
[58] Ira M. Hall,et al. BEDTools: a flexible suite of utilities for comparing genomic features , 2010, Bioinform..
[59] A. Look,et al. Studying peripheral sympathetic nervous system development and neuroblastoma in zebrafish. , 2010, Methods in cell biology.
[60] H. Shimada,et al. Pathology of peripheral neuroblastic tumors: Significance of prominent nucleoli in undifferentiated/poorly differentiated neuroblastoma , 2008, Pathology & Oncology Research.
[61] D. Stram,et al. Comprehensive analysis of chromosome 1p deletions in neuroblastoma. , 2001, Medical and pediatric oncology.